Global Health Highlights: Obesity Pills, Ebola Facilities, and Screwworm Outbreaks

This article summarizes significant health news, including Structure's obesity pill showing no liver injury, the US plan for an Ebola facility in Kenya, and increased Ebola response funding. Other topics include promising obesity drug trials, screwworm detection in Texas, and the FDA's policy shift favoring tobacco companies.

Recent health developments include Structure Therapeutics' experimental obesity pill aleniglipron showing no signs of liver injury while aiding weight loss in patients. Despite low dropout rates, the drug shows promise in the battle against obesity.

In response to the unfolding Ebola situation, U.S. funding for response efforts in the Democratic Republic of Congo has been increased to over $200 million. Kenyan President William Ruto backs the U.S. plan to establish an Ebola quarantine facility in Kenya despite local protests.

Meanwhile, Texas faces a livestock quarantine as the screwworm parasite resurfaces, creating concerns among ranchers and pet owners. The FDA's shift in policy allows some tobacco products to enter the market without licenses, sparking discussions on tobacco industry influence.